Shanghai Huamao Pharmaceutical

Shanghai Huamao Pharmaceutical is a Chinese pharmaceutical company headquartered in Shanghai, specializing in the development and large-scale production of chemical active pharmaceutical ingredients (APIs) and finished oral medications. The company maintains a strong focus on chronic disease management, particularly within the therapeutic areas of endocrinology and cardiology. Its commercial portfolio features widely used generic treatments for type 2 diabetes, such as metformin hydrochloride and gliclazide, as well as cardiovascular drugs like amlodipine. Huamao operates modern, GMP-certified manufacturing facilities in the Qingpu Industrial Zone, ensuring high standards of quality for both domestic supply and international export. By integrating API synthesis with final product formulation, the company achieves significant cost efficiencies and supply chain reliability.